The Trump administration is considering Sara Brenner, a senior adviser at the Department of Health and Human Services and associate of Health Secretary Robert F. Kennedy Jr., along with Jeff Vacirca, chief executive of a New York oncology practice, for leadership roles at the Food and Drug Administration.
The move follows the White House's withdrawal Tuesday of its prior nominee, White House aide Heidi Overton, whose confirmation faced insufficient Senate support. The agency has operated without a permanent commissioner since former FDA head Marty Makary resigned in May amid staff reductions and policy disputes.
Brenner, a physician who previously served as the FDA's top deputy, has joined Kennedy at events including the launch of an initiative to examine vaccine injuries. Vacirca has led New York Cancer & Blood Specialists since 2008. Neither responded to requests for comment.
The incoming FDA leaders are expected to prioritize faster clinical trials and revised reviews for rare disease treatments. The agency also oversees vaccines and peptides, areas of focus for Kennedy's Make America Healthy Again efforts.
This development reflects ongoing efforts within the administration to install officials supportive of Kennedy's reform priorities at the FDA after a period of leadership turnover.
Comments
No comments yet. Be the first to share your thoughts.